Elinzanetant, a new non-hormonal drug, has shown promise in reducing the frequency and severity of vasomotor symptoms in menopausal women, including hot flashes and night sweats. In a phase 3 clinical trial conducted by Bayer, the drug was found to significantly improve sleep quality and overall quality of life in postmenopausal women experiencing moderate to severe symptoms. The results have been submitted to the FDA for approval. Elinzanetant works by blocking brain chemicals responsible for these symptoms, offering a potential non-estrogen treatment option for menopausal women who may be concerned about the side effects of hormone therapy.
Source link